ArticleCancers2023

Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer.

George Raynes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.